India, June 23 -- A new FDA approval is set to bring clearer dosing information to women using the TWIRLA birth control patch, a once-weekly hormonal contraceptive designed for women with a BMI under 30.
TWIRLA was first approved by the FDA on February 14, 2020, as a low-dose combined hormonal contraceptive patch for birth control.
Exeltis USA, Inc. announced that the agency has approved an update to the labeled strength of the patch to better reflect the amount of hormone actually delivered to the body.
The updated strength - expected to appear on the market in September or October 2026 - is based on findings from Study ATI-CL28, which measured the residual drug left in the patch after use. According to Exeltis, the change aligns with F...